Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen (formaldehyde Inactivated)

For adults aged 18 to 64 years, the standard dose of the vaccine containing the Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen is a single 0.5 mL intramuscular (IM) injection. This is typically administered once annually, usually in the autumn months (September through November in the Northern Hemisphere) to ensure peak immunity during the height of the flu season. For adults 65 years and older, a 'high-dose' version may be utilized, which contains four times the amount of antigen (60 mcg of HA per strain instead of 15 mcg) to compensate for immunosenescence (the natural weakening of the immune system with age).

The dosage for children depends heavily on age and prior vaccination history:

• Infants 6 months to 35 months: Traditionally, a 0.25 mL dose was used, though many modern formulations now utilize a full 0.5 mL dose.
• Children 3 years to 17 years: A single 0.5 mL IM injection.
• Priming Dose: For children aged 6 months through 8 years who are receiving their first-ever influenza vaccination (or who have not previously received at least two doses), a two-dose series is required. The doses should be administered at least 4 weeks apart. This ensures the 'priming' of the naive immune system to recognize the H1N1 Guangdong-Maonan antigen effectively.

Renal Impairment

No dosage adjustment is required for patients with renal insufficiency or those on hemodialysis. The antigen does not rely on renal clearance for its efficacy or safety profile.

Hepatic Impairment

No dosage adjustment is necessary for patients with hepatic impairment. The liver does not play a role in the processing of viral antigens or the subsequent production of antibodies.

Elderly Patients

As noted, elderly patients (65+) may receive either the standard dose or a high-dose (HD) or adjuvanted (MF59) vaccine. Clinical trials suggest that the high-dose formulations provide superior protection against hospitalization in this demographic.

This medication is administered exclusively by a healthcare professional. It should be injected into the deltoid muscle of the upper arm in adults and older children. In infants and small children, the anterolateral thigh (vastus lateralis) is the preferred site due to greater muscle mass.

• Preparation: The vial or syringe should be shaken well before administration to ensure a homogenous suspension. It should appear as a slightly opalescent or white liquid.
• Storage: The antigen must be stored under strict 'cold chain' conditions between 2°C and 8°C (36°F to 46°F). It must never be frozen; freezing destroys the structural integrity of the formaldehyde-inactivated proteins, rendering the vaccine useless.
• Food/Drink: There are no restrictions on food or drink before or after the injection.

If you miss the annual window for the flu shot, it is generally recommended to receive it as soon as possible, even as late as January or February, as flu activity can persist into late spring. For children requiring two doses, if the second dose is missed, it should be administered at the earliest opportunity.

An overdose of an inactivated influenza antigen is highly unlikely as it is administered in pre-measured single-dose units. However, an accidental double dose would likely only increase the risk of local injection site reactions (soreness, swelling). There is no specific 'antidote,' and management would be supportive (e.g., acetaminophen for pain).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

The most frequently reported side effects associated with the Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen are local to the injection site. These are signs that the immune system is responding to the antigen.

• Injection Site Pain: A dull ache or soreness in the deltoid, typically beginning 6-12 hours after the shot and lasting 24-48 hours.
• Erythema (Redness): A small red patch at the needle entry point.
• Induration (Hardness): A firm area around the injection site.
• Malaise and Fatigue: A general feeling of tiredness as the body diverts energy to antibody production.
• Headache: Usually mild and responsive to over-the-counter analgesics.

• Low-grade Fever: Temperature usually below 101°F (38.3°C).
• Myalgia (Muscle Aches): Generalized body aches, often mistaken for a 'mild flu.'
• Arthralgia (Joint Pain): Mild stiffness in the joints.
• Nausea: Occasional gastrointestinal upset, though rare in adults.
• Shivering/Chills: Brief episodes of feeling cold as the immune system ramps up.

• Lymphadenopathy: Swelling of the lymph nodes in the armpit (axilla) on the side of the injection.
• Urticaria (Hives): A mild allergic skin reaction.
• Syncope (Fainting): Often a vasovagal response to the needle itself rather than the antigen.

> Warning: Stop taking Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen (formaldehyde Inactivated) and call your doctor immediately if you experience any of these.

• Anaphylaxis: A severe, life-threatening allergic reaction characterized by swelling of the throat, difficulty breathing, rapid heart rate, and a drop in blood pressure. This typically occurs within minutes of injection.
• Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis. The risk is estimated at 1-2 additional cases per million doses.
• Angioedema: Deep swelling of the skin, particularly around the eyes or lips.
• High Fever: A temperature exceeding 103°F (39.4°C).
• Facial Palsy (Bell's Palsy): Sudden weakness in the facial muscles (very rare and controversial association).

There are no known long-term side effects associated with the annual administration of inactivated influenza antigens. The antigen is cleared from the body within weeks, leaving only the 'memory' of the immune response. Some studies have looked into 'original antigenic sin,' where previous exposures affect subsequent responses, but this is a matter of immunological efficacy rather than a safety concern.

There are currently no FDA black box warnings for Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen (formaldehyde Inactivated). It is considered one of the safest medical interventions available. However, the package insert always contains a warning regarding the potential for GBS if the patient has a prior history of the condition within 6 weeks of a previous flu vaccination.

Report any unusual symptoms to your healthcare provider.

Before receiving a vaccine containing the Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen, it is vital to disclose your full medical history to your healthcare provider. While inactivated vaccines cannot cause the flu, they do interact with the immune system in ways that require caution in certain populations.

No FDA black box warnings for Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen (formaldehyde Inactivated).

• Allergic Reactions / Anaphylaxis: If you have a known severe allergy to any component of the vaccine, including formaldehyde (used in the inactivation process) or egg proteins (if the vaccine was egg-propagated), you must inform your provider. While most people with egg allergies can safely receive the vaccine, those with a history of severe anaphylaxis to eggs should be vaccinated in a medical setting capable of managing severe allergic reactions.
• Guillain-Barré Syndrome (GBS): If you have ever developed GBS within 6 weeks of a previous influenza vaccination, the decision to receive this antigen should be carefully weighed by your doctor.
• Acute Febrile Illness: Vaccination should typically be deferred in individuals with moderate or severe acute illness, with or without fever, to avoid diagnostic confusion between the illness and potential vaccine side effects.
• Immunocompromised States: Patients with HIV, cancer, or those taking immunosuppressive drugs may have a diminished immune response to the antigen. It is not a safety risk, but the vaccine may be less effective.

There are no specific laboratory tests (like blood counts or liver panels) required before or after receiving this antigen. However, patients should be monitored for 15 minutes post-injection in the clinic to ensure no immediate hypersensitivity reactions occur. For certain populations, such as those on anticoagulants, monitoring for hematoma (bruising) at the injection site is advised.

The antigen has no known effect on the ability to drive or operate machinery. If you experience dizziness or syncope (fainting) after the injection, you should wait until these symptoms resolve before driving.

There is no direct interaction between alcohol consumption and the Influenza A (H1N1) antigen. However, excessive alcohol use can suppress the immune system, potentially reducing the effectiveness of the antibody response. Moderate consumption is generally not a concern.

As this is a single-dose (or two-dose) intervention, 'discontinuation' is not applicable in the same way as chronic medication. However, if a patient experiences a severe reaction to the first dose of a two-dose pediatric series, the second dose should be withheld.

> Important: Discuss all your medical conditions with your healthcare provider before starting Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen (formaldehyde Inactivated).

There are no absolute drug-drug contraindications that would prevent the administration of the Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen. However, it should not be given simultaneously with other vaccines in the same limb if a severe local reaction is anticipated, though even this is a precaution rather than a contraindication.

• Immunosuppressants (e.g., Cyclosporine, Methotrexate, TNF-blockers): These drugs may significantly reduce the immune system's ability to respond to the antigen. The clinical consequence is not toxicity, but rather vaccine failure. Patients may still be susceptible to the H1N1 virus despite vaccination. Doctors may recommend timing the vaccine during a 'window' of lower immunosuppression if possible.
• Chemotherapy: Similar to immunosuppressants, active chemotherapy can blunt the HI titer response. Vaccination is usually recommended at least 2 weeks before starting chemo or between cycles.
• High-Dose Corticosteroids: Prednisone doses of 20 mg/day or higher can interfere with the development of active immunity.

• Antiviral Medications (Oseltamivir, Zanamivir): While these do not interfere with inactivated vaccines like the Guangdong-Maonan antigen, they do interfere with live attenuated (nasal spray) vaccines. For the inactivated injection, there is no known interaction.
• Anticoagulants (Warfarin, Heparin, DOACs): There is an increased risk of hematoma (deep bruising) at the injection site. Use a fine-gauge needle and apply firm pressure for at least 2 minutes.

There are no known interactions with grapefruit, dairy, or high-fat meals. The antigen is not processed via the digestive tract.

• Echinacea and Elderberry: Some patients take these to 'boost' the immune system. While there is no evidence of harm, there is also no clinical data suggesting they improve the vaccine's efficacy.
• St. John's Wort: No interaction, as this antigen does not utilize the CYP3A4 pathway.

• False Positive Serology: In rare cases, influenza vaccination has been associated with transient false-positive results in enzyme immunoassays (EIA) for HIV-1, Hepatitis C, and HTLV-1. If a positive result occurs shortly after vaccination, a more specific confirmatory test (like a Western Blot or PCR) should be performed. The mechanism is thought to be the production of cross-reactive IgM antibodies.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen (formaldehyde Inactivated) must NEVER be used in the following circumstances:

1. 1Severe Allergic Reaction (Anaphylaxis): Any individual who has had a documented life-threatening reaction to a previous dose of any influenza vaccine or to any specific component of this vaccine (e.g., formaldehyde, polymyxin, neomycin) should not receive it. The mechanism is an IgE-mediated hypersensitivity that can lead to airway obstruction and shock.
2. 2Infants Under 6 Months: The safety and efficacy of this antigen have not been established in infants younger than 6 months. Their immune systems are generally too immature to mount a protective response, and they rely on maternal antibodies.

Conditions requiring a careful risk-benefit analysis include:

• History of Guillain-Barré Syndrome (GBS): Specifically if it occurred within 6 weeks of a previous flu shot. The risk of recurrence is low but must be discussed.
• Moderate to Severe Acute Illness: To avoid masking symptoms of the illness or attributing them to the vaccine.
• Severe Egg Allergy: If the antigen was produced in eggs, it should only be administered in a setting where medical supervision is available, although the CDC now states most egg-allergic individuals can receive any flu vaccine.

Patients sensitive to formaldehyde (used in many industrial applications and as a preservative) may react to the trace amounts left in the vaccine. Additionally, those sensitive to certain antibiotics used during the manufacturing process (like Neomycin) may show cross-sensitivity.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen (formaldehyde Inactivated).

Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen is strongly recommended for pregnant individuals. According to the CDC and ACOG (2024), the flu vaccine is safe in all trimesters. Pregnant women are at a significantly higher risk for severe complications, including pneumonia and hospitalization, from the H1N1 virus due to changes in the immune system, heart, and lungs. Furthermore, vaccination during pregnancy provides 'passive immunity' to the newborn, protecting the infant during the first 6 months of life when they are too young to be vaccinated themselves. No evidence of teratogenicity (birth defects) has been linked to this inactivated antigen.

This antigen is safe for use during breastfeeding. The inactivated viral fragments do not pass into breast milk in a way that could harm the infant. However, the antibodies produced by the mother (IgA) can pass into the milk, potentially providing additional respiratory protection for the nursing child.

Approved for children aged 6 months and older. It is critical to follow the two-dose schedule for children under 9 years old who are receiving the antigen for the first time. The A/Guangdong-Maonan strain has been extensively studied in pediatric populations and is essential for preventing 'pediatric flu-related deaths,' which occur even in previously healthy children.

Individuals aged 65 and older are at the highest risk for death from Influenza A (H1N1). While the standard dose is safe, the immune response may be weaker. Geriatric patients should prioritize 'enhanced' vaccines (High-Dose or Adjuvanted) if available. There is no increased risk of falls or cognitive impairment associated with this antigen.

Patients with chronic kidney disease (CKD) are considered high-risk for flu complications. The antigen is safe and recommended for this group. No dose adjustment is needed for any stage of CKD or for those on dialysis.

Safe for use in patients with cirrhosis or other liver diseases. These patients are often immunocompromised and should be prioritized for annual vaccination to prevent secondary bacterial pneumonia.

> Important: Special populations require individualized medical assessment.

The Influenza A Virus A/guangdong-maonan/swl1536/2019 Cnic-1909 (h1n1) Antigen acts as an immunogen. The primary molecular target is the B-cell receptor (BCR) on naive B-lymphocytes. Upon binding to the Hemagglutinin (HA) epitopes on the inactivated virus, the BCR triggers a signal transduction cascade involving tyrosine kinases (Syk, Lyn). This leads to the internalisation of the antigen, its processing, and presentation to T-cells. The ultimate result is the production of high-affinity neutralizing antibodies. These antibodies bind to the 'head' region of the HA protein of the circulating H1N1 virus, sterically hindering its ability to bind to alpha-2,6-linked sialic acid receptors on the human respiratory epithelium.

The pharmacodynamic effect is measured by the Hemagglutination Inhibition (HI) antibody titer.

• Onset: Initial antibody rise begins 7 days post-injection.
• Peak: Maximum titers are achieved between 14 and 28 days.
• Duration: Protective levels typically persist for 6 to 12 months.
• Tolerance: Not applicable, though repeated annual exposure to similar strains can lead to 'blunting' of the incremental antibody rise, a phenomenon known as the 'ceiling effect.'

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular) |

| Protein Binding | N/A (Antigenic processing) |

| Half-life (Antigen) | ~24-48 hours (at injection site) |

| Tmax (Antibody) | 14-21 days |

| Metabolism | Lysosomal Proteolysis |

| Excretion | Reticuloendothelial clearance |

The antigen consists of purified viral subunits. The molecular weight of the Hemagglutinin trimer is approximately 220 kDa. It is soluble in phosphate-buffered saline (PBS). The formaldehyde inactivation process involves the creation of methylene bridges between amino groups in the viral proteins, which stabilizes the structure against thermal degradation while eliminating infectivity.

This agent is classified as an Inactivated Viral Vaccine Antigen. It is specifically part of the H1N1 pdm09-like lineage. Related medications include the A/Victoria/2570/2019 (H1N1)pdm09-like antigens and various H3N2 and Influenza B components found in seasonal vaccines.